(Q34205869)

English

The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1 reference

based on heuristic

inferred from title

David Flockhart

6

object named as

David A Flockhart

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

author name string

Wenjie Jessie Lu

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Cong Xu

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Zifan Pei

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Abdelrahman S Mayhoub

4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Mark Cushman

5

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

language of work or name

0 references

publication date

4 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

133

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

99-109

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

https://scigraph.springernature.com/pub.10.1007/s10549-011-1699-4

0 references

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Selective estrogen receptor modulators: structure, function, and clinical use.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

The pharmacology and clinical uses of tamoxifen

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Tamoxifen, hot flashes and recurrence in breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Orally administered endoxifen is a new therapeutic agent for breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19).

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Lead optimization of 4-imidazolylflavans: new promising aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Retinol inhibits aromatase activity and expression in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Anti-aromatase activity of phytochemicals in white button mushrooms (Agaricus bisporus).

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxy-phenyl)-retinamide

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Pomegranate ellagitannin-derived compounds exhibit antiproliferative and antiaromatase activity in breast cancer cells in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Methadone: a substrate and mechanism-based inhibitor of CYP19 (aromatase).

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Structural basis for androgen specificity and oestrogen synthesis in human aromatase

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Improved protein-ligand docking using GOLD

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs).

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Activated PKCalpha/ERK1/2 signaling inhibits tamoxifen-induced apoptosis in C6 cells

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Tamoxifen inhibits particulate-associated protein kinase C activity, and sensitises cultured human glioblastoma cells not to etoposide but to gamma-radiation and BCNU.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1699-4

21 January 2018

Identifiers

10.1007/S10549-011-1699-4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34205869&oldid=1962110775"